StonvexLoading…
StonvexStonvexStonvexCore line items from GYRE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $22.52M | $116.59M | $79.39M | $48.83M |
Operating Income | $-9.36M | $11.49M | $11.37M | $4.44M |
Net Income | $-9.86M | $9.88M | $11.20M | $1.58M |
EPS (Diluted) | $-0.10 | $0.02 | $0.04 | $0.01 |
Total Assets | $162.01M | $166.13M | $159.38M | $152.65M |
Total Liabilities | $25.03M | $23.85M | $21.97M | $23.20M |
Cash & Equivalents | $37.50M | $37.07M | $40.40M | $36.49M |
Free Cash Flow OCF − CapEx | $3.00M | $-180.00K | $5.59M | $1.58M |
Shares Outstanding | 91.34M | 91.31M | 90.89M | 90.82M |